Details for Patent: 8,012,999

Title:	Modulators of CFTR
Abstract:	Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
Inventor(s):	Hadida Ruah; Sara S. (La Jolla, CA), Grootenhuis; Peter D. J. (San Diego, CA), Zhou; Jinglan (San Diego, CA), Bear; Brian Richard (Oceanside, CA), Miller; Mark T. (San Diego, CA), McCartney; Jason (Cardiff by the Sea, CA)
Assignee:	Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Filing Date:	May 19, 2010
Application Number:	12/782,967
Claims:	1. A method of treating or lessening the severity of a disease in a patient, wherein said disease is dry-eye disease, said method comprising the step of administering to said patient an effective amount of a compound according to formula I: ##STR00021## or a pharmaceutically acceptable salt thereof, wherein independently for each occurrence: m is 0-4; R.sub.M is --Z.sup.MR.sub.11, wherein each Z.sup.M is a bond or an optionally substituted branched or straight C.sub.1-6 aliphatic chain wherein up to two carbon units of Z.sup.M are optionally replaced by --CO--, --CS--, --CONR.sup.N--, --CO.sub.2--, --OCO--, --NR.sup.NCO.sub.2--, --O--, --OCONR.sup.N--, --NR.sup.NCO--, --S--, --SO--, --SO.sub.2--, or --NR.sup.N--; R.sub.11 is R.sup.N, halo, --OH, --NH.sub.2, --NO.sub.2, --CN, --CF.sub.3, or --OCF.sub.3; R.sup.N is H or an optionally substituted C1-C8 aliphatic; R.sub.1 is a C1-C6 aliphatic; R.sub.2 is H or an optionally substituted C1-C6 aliphatic; R.sub.3 and R'.sub.3 together with the carbon atom to which they are attached form an unsubstituted C.sub.3-7 cycloalkyl ring; and R.sub.4 is: ##STR00022## 2. The method of claim 1, wherein R.sub.1 is an optionally substituted C1-C4 aliphatic. 3. The method of claim 1, wherein R.sub.1 is an optionally substituted C1-C4 alkyl. 4. The method of claim 1, wherein R.sub.1 is methyl, ethyl, propyl, or butyl. 5. The method of claim 1, wherein R.sub.2 is H. 6. The method of claim 1, wherein R.sub.2 is a C1-C6 aliphatic. 7. The method of claim 1, wherein R.sub.2 is a C1-C6 alkyl. 8. The method of claim 1, wherein R.sub.2 is methyl, ethyl, propyl, butyl, pentyl, or hexyl. 9. The method of claim 1, wherein R.sub.3 and R'.sub.3 taken together form a cyclopropyl ring. 10. The method of claim 1, wherein R.sub.3 and R'.sub.3 taken together form a cyclopentyl ring. 11. The method of claim 1, wherein R.sub.4 is ##STR00023## 12. The method of claim 1, wherein R.sub.4 is ##STR00024## 13. The method of claim 1, wherein m is 0. 14. The method of claim 1, wherein the compound is according to formula II: ##STR00025## 15. The method of claim 14, wherein R.sub.1 is methyl. 16. The method of claim 14, wherein m is 0. 17. The method of claim 1, wherein the compound is according to formula III: ##STR00026## 18. The method of claim 17, wherein R.sub.1 is methyl. 19. The method of claim 17, wherein m is 0. 20. The method of claim 1, wherein the compound is ##STR00027##